Cost-effectiveness analysis of a fixed-dose combination of indacaterol and glycopyrronium as maintenance treatment for COPD

OBJECTIVE: The aim of this study was to evaluate the cost-effectiveness of the long-acting beta-2 agonist (LABA)/long-acting muscarinic antagonist (LAMA) dual bronchodilator indacaterol/glycopyrronium (IND/GLY) as a maintenance treatment for COPD patients from the perspective of health care payer in...

Descripción completa

Detalles Bibliográficos
Autores principales: Chan, Ming-Cheng, Tan, Elise Chia-Hui, Yang, Ming-Chin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5894684/
https://www.ncbi.nlm.nih.gov/pubmed/29670344
http://dx.doi.org/10.2147/COPD.S159103

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5894684/
https://www.ncbi.nlm.nih.gov/pubmed/29670344
http://dx.doi.org/10.2147/COPD.S159103

Ejemplares similares